Multiorgan microfluidic platform with breathable lung chamber for inhalation or intravenous drug screening and development
- 14 October 2019
- journal article
- research article
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (2) , 486-497
Abstract
Efficient and economical delivery of pharmaceuticals to patients is critical for effective therapy. Here we describe a multiorgan (lung, liver, and breast cancer) microphysiological system (“Body‐on‐a‐Chip”) designed to mimic both inhalation therapy and/or intravenous therapy using curcumin as a model drug. This system is “pumpless” and self‐contained using a rocker platform for fluid (blood surrogate) bidirectional recirculation. Our lung chamber is constructed to maintain an air‐liquid interface and contained a “breathable” component that was designed to mimic breathing by simulating gas exchange, contraction and expansion of the “lung” using a reciprocating pump. Three cell lines were used: A549 for the lung, HepG2 C3A for the liver, and MDA MB231 for breast cancer. All cell lines were maintained with high viability (>85%) in the device for at least 48 hr. Curcumin is used to treat breast cancer and this allowed us to compare inhalation delivery versus intravenous delivery of the drug in terms of effectiveness and potentially toxicity. Inhalation therapy could be potentially applied at home by the patient while intravenous therapy would need to be applied in a clinical setting. Inhalation therapy would be more economical and allow more frequent dosing with a potentially lower level of drug. For 24 hr exposure to 2.5 and 25 µM curcumin in the flow device the effect on lung and liver viability was small to insignificant, while there was a significant decrease in viability of the breast cancer (to 69% at 2.5 µM and 51% at 25 µM). Intravenous delivery also selectively decreased breast cancer viability (to 88% at 2.5 µM and 79% at 25 µM) but was less effective than inhalation therapy. The response in the static device controls was significantly reduced from that with recirculation demonstrating the effect of flow. These results demonstrate for the first time the feasibility of constructing a multiorgan microphysiological system with recirculating flow that incorporates a “breathable” lung module that maintains an air‐liquid interface.Keywords
Funding Information
- Foundation for the National Institutes of Health (5R44TR001326‐02)
- National Science Foundation (NNCI‐1542081)
This publication has 34 references indexed in Scilit:
- Design Optimization of Liquid-Phase Flow Patterns for Microfabricated Lung on a ChipAnnals of Biomedical Engineering, 2012
- The Role of Body-on-a-Chip Devices in Drug and Toxicity StudiesAnnual Review of Biomedical Engineering, 2011
- Bio-inspired, efficient, artificial lung employing air as the ventilating gasLab on a Chip, 2011
- A Simple Hanging Drop Cell Culture Protocol for Generation of 3D SpheroidsJournal of Visualized Experiments, 2011
- The air-liquid interface and use of primary cell cultures are important to recapitulate the transcriptional profile of in vivo airway epitheliaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2011
- Combination of fluid and solid mechanical stresses contribute to cell death and detachment in a microfluidic alveolar modelLab on a Chip, 2010
- A microfluidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chipLab on a Chip, 2010
- An open-access microfluidic model for lung-specific functional studies at an air-liquid interfaceBiomedical Microdevices, 2009
- Gravity‐induced convective flow in microfluidic systems: Electrochemical characterization and application to enzyme‐linked immunosorbent assay testsElectrophoresis, 2004
- Characterization of the A549 Cell Line as a Type II Pulmonary Epithelial Cell Model for Drug MetabolismExperimental Cell Research, 1998